We report our retrospective analysis on 34 relapsed/refractory Multiple Myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14 males. Median age was 73.2. Daratumumab was associated to lenalidomide in and dexamethasone (DRd) in 30 (88,3%) and to bortezomib and dexamethasone (DVd) in 4 cases (11,7%). The ORR was 88%. CR occurred in 12% of cases, VGPR in 44% and PR in 32%. The 12 months PFS and OS rates were 78% and 86,5%, respectively. Present data confirm those recently reported in the literature and further reinforce the early use of daratumumab-based triplets for RRMM patients
Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma. A “real world” experience / Fucci, Ludovica; Gensini, Lorenzo; Coppetelli, Ugo; Ortu La Barbera, Elettra; Gentile, Martina; Fiori, Luciano; Perrone, Salvatore; Cimino, Giuseppe. - In: LEUKEMIA RESEARCH REPORTS. - ISSN 2213-0489. - (2022). [10.1016/j.lrr.2022.100330]
Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma. A “real world” experience
Ludovica Fucci;Martina Gentile;Giuseppe Cimino
2022
Abstract
We report our retrospective analysis on 34 relapsed/refractory Multiple Myeloma (RRMM) patients treated with daratumumab based triplets. Twenty patients were females and 14 males. Median age was 73.2. Daratumumab was associated to lenalidomide in and dexamethasone (DRd) in 30 (88,3%) and to bortezomib and dexamethasone (DVd) in 4 cases (11,7%). The ORR was 88%. CR occurred in 12% of cases, VGPR in 44% and PR in 32%. The 12 months PFS and OS rates were 78% and 86,5%, respectively. Present data confirm those recently reported in the literature and further reinforce the early use of daratumumab-based triplets for RRMM patients| File | Dimensione | Formato | |
|---|---|---|---|
|
Fucci_post-print_Daratumumab_2022.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
730.38 kB
Formato
Adobe PDF
|
730.38 kB | Adobe PDF | |
|
Fucci_Daratumumab_2022.pdf
accesso aperto
Note: https://www.sciencedirect.com/science/article/pii/S2213048922000425?via=ihub
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
741.76 kB
Formato
Adobe PDF
|
741.76 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
